Skip to main content
. 2022 Jul 14;1(3):91–98. doi: 10.1016/j.jacig.2022.05.005

Table II.

Differences between RSV and non-RSV bronchiolitis at different ages

Characteristic < 3 mo
3 to <6 mo
6 to <12 mo
12-24 mo
RSV (405) No RSV (172) P value RSV (184) No RSV (133) P value RSV (163) No RSV (119) P value RSV (86) No RSV (53) P value
Demographic characteristics
 Sex ( male) 48% 38% .02 46.2% 41.4% .42 43% 40% .62 39% 51% .16
 Preterm 12% 17% .10 20.1% 32.3% .01 16.6% 25.2% .09 27.9% 11.3% .03
 Malnutrition 18.6% 24% .17 15.8% 27.3% .01 14.7% 23.5% .06 29% 17.6% .15
Laboratory test results
 Hemoglobin level 11 (10-12) 11 (10-13) .44 11 (10-12) 11 (10-11.5) .10 11 (10-11.5) 11 (10-12) .56 11(10-12) 12 (11-13) .68
 WBC count (× 103) 10.3 (8-13) 10 (8-13) .84 12 (9-16) 13 (9-15) .76 12 (9-15) 13 (10-14) .52 12 (9-15) 11 (8-16) .73
 Neuthrophil count (× 103) 4.1 (2.5-6) 3.7 (2-5) .74 6 (3-7.6) 5 (4-8.5) .62 6 (4-8) 6 (4-8.7) .55 6 (5-9) 6 (4-11) .91
 Lymphocyte count (× 103) 4.7 (3.2-6) 5 (3.5-7) .33 5 (4-7.1) 4 (3-5.9) .13 4.6 (3-5) 4.4 (3-6) .89 4 (3-5) 3 (2 -4) .60
 CRP level 1.5 (0.4-3) 1 (0.2-2) .52 1.5 (0.6-3) 1 (0.5-2) .56 2 (0.8-5) 1.9 (0.8-4) .62 2 (0.7-4) 1.6 (0.7-4) .73
Radiologic findings
 Radiologic evaluation 150 (37%) 52 (30.2%) .12 73 (39.7%) 55 (41.4%) .80 85 (52.1%) 56 (47%) .46 51 (59.3%) 20 (37.7%) .01
 No findings 89 (59.3%) 29 (55.8%) .74 24 (32.8%) 29 (52.7%) .04 43 (50.6%) 30 (53.6%) .73 17 (33.3%) 5 (25%) .58
 Atelectasis 19 (12.7%) 4 (7.7%) .45 14 (19.2%) 4 (7.3%) .07 4 (4.7%) 0 (0%) .15 0 (0%) 0 (0%) .99
 Focal consolidation 40 (26.7%) 19 (36.5%) .21 35 (47.9%) 22 (40%) .47 37 (43.5%) 26 (46.4%) .86 34 (66.7%) 15 (75%) .57
 Pneumothorax 2 (1.3%) 0 (0%) .99 0 (0%) 0 (0%) .99 1 (1.2%) 0 (0%) .99 0 (0%) 0 (0%) .99
Treatments
 Antibiotics (%) 20% 19% .73 25% 26% .89 39% 32% .31 53% 34% .03
 Bronchodilators 65% 69% .47 73% 85% .01 87% 94% .02 88% 93% .72
 Systemic steroids 0.5% 2.5% .06 2.5% 8.5% .03 11% 21% .02 37% 39% .85
 Intravenous fluids 43.5% 28.5% <.01 44.6% 21.8% <.01 35% 28.6% .30 38.5% 22.7% .07
 Enteral feeding 28% 12% <.01 21.2% 13.5% .10 12.3% 10% .70 6% 2% .40
Parameters of disease severity
 Severity score ≥ 8 (%) 43% 26% <.01 36.4% 22% .01 32% 22% .14 24% 15% .32
 Severity score 5 (4-9) 5 (4-8) <.01 5 (4-8) 5 (4-6) <.01 5 (4-8) 5 (4-6) .27 5 (4-7) 5 (4-6) .84
 Apnea 22% 25% .84 8% 9% .81 1.5% 3.5% .24 2.3% 0% .52
 LOS 6 (4-9) 4 (2-6.2) <.01 5 (3-7) 5 (3-8) .35 4 (3-7) 4 (2-6) .08 4 (2-6) 3 (2-5) .14
 Duration of O2 (d) 5 (2-7) 2 (1-5) <.01 4 (2-6) 3 (2-5) .04 3 (2-5) 2 (1-4) .02 3 (1-5) 2 (1-3) .10
 HFNC 43.7% 26.7% <.01 38% 22% <.01 27% 21% .26 22.1% 22.6% .90
 PICU admission 28.6% 14.5% <.01 18.5% 10.5% .05 9.8% 9.2% .90 9.3% 1.9% .15
 Time in PICU (d) 4 (2-7) 3 (2-7) .29 4 (2-5) 3 (2-5) .44 3 (1-4) 2.5 (2-4) .76 5 (2-9) 3 (3-3) .80
 CPAPP/BiPAP 26.5% 10.5% <.01 17.4% 9% .04 8% 9.25% .82 8% 1.9% .15
 MV 4.2% 1.7% .21 2.2% 0% .14 0% 0.8% .42 1.2% 0% .90

This table displays total bronchiolitis cases (ie, RSV bronchiolitis and non-RSV bronchiolitis cases). The treatment section reflects the need for antibiotics, bronchodilators, steroids, intravenous fluids, or enteral nutrition at any time during admission. Continuous variables were analyzed by using the Mann-Whitney U test, and categoric variables were analyzed by using the Fisher exact or chi-square test. Data are reported as medians and IQRs (25%-75%). Boldface indicates statistical significance.

CRP, C-reactive protein; MV, mechanical ventilation; WBC, white blood cell.